News AbbVie pays Gubra $350m upfront to enter obesity field AbbVie has joined the ranks of pharma groups trying to develop weight-loss drugs, licensing an amylin agonist from Gubra in a $2.2bn-plus deal.
News AbbVie closes on Rinvoq approval in inflamed artery disease AbbVie's Rinvoq is poised to become the first oral targeted treatment for giant cell arteritis in the EU after being backed by the CHMP.
News FDA clears new antibiotic for superbug infections AbbVie has won FDA approval for Emblaveo, a new antibiotic to treat pathogens that pose serious public health threats.
R&D JP Morgan Week 2025 – Steve Pakola On the sidelines of JP Morgan in San Francisco, editor-in-chief Jonah Comstock caught up with Steven Pakola, REGENXBIO’s chief medical officer.
News AbbVie adds psoriasis med with Nimble takeover AbbVie agrees a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will add an oral peptide for psoriasis to its pipeline.
News AbbVie bags EU nod for key drug from ImmunoGen takeover AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically cleared for folate receptor-alpha (FRα) positive, platinum-resistant
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.